Asan Medical Center: Leukemia trials

The registry lists 20 Leukemia studies with Asan Medical Center as lead sponsor. 1 are open to participants now and 1 have results posted.

Phase 1 3Phase 2 12Phase 3 1No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.Enrolling by invitationNCT03507842Phase 3
• Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00844298Phase 2Results posted
• HCT With PTCy in Higher-risk MDSActive, not recruitingNCT06098313Phase 2
• Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDSTerminatedNCT02477787Phase 2
• Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)TerminatedNCT02428517
• Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)WithdrawnNCT02421926
• Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell TransplantationCompletedNCT01795378Phase 1/2
• Chronic Myelod Leukemia Registry at Asan Medical CenterTerminatedNCT01761695
• Acute Lymphoblastic Leukemia Registry at Asan Medical CenterTerminatedNCT01761682
• HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid TumorsStatus unknownNCT01509300Phase 1/2
• Pharmacogenomics Validation for Imatinib in Chronic Myeloid LeukemiaCompletedNCT01437202
• Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic LeukemiaStatus unknownNCT01429610Phase 2
• Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid LeukemiaCompletedNCT01050036Not applicable
• Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)TerminatedNCT01037764Phase 2
• Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in RemissionCompletedNCT01020734Phase 2
• Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced CancerCompletedNCT00823524Phase 1/2
• Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic SyndromeCompletedNCT00732316Phase 2
• Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological CancerCompletedNCT00627666Phase 2
• Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00618501Phase 2
• Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other DiseaseCompletedNCT00521430Not applicable